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Background: Allopurinol is an effective urate-lowering drug that is well tolerated by the majority of patients.
Patients with chronic renal insufficiency have an increased risk of hypersensitivity reactions with allopurinol.
Case presentation: 75 year old male patient with gout, renal insufficiency, history of metastatic colorectal
carcinoma status post-resection was referred to Allergy clinic for a maculopapular eruption that developed 1 week
after initiating therapy with allopurinol. The rash resolved with discontinuation of allopurinol. However, his serum
urate level rose to 19.9 mg/dl. We initially proposed a slow 4 week oral allopurinol desensitization. The treating
nephrologist felt it was critical to lower urate more rapidly. As a result, we modified the dose and standard 4 week
protocol down to 2 weeks. A suspension of allopurinol was prepared by the allergy nurse practitioner with a
300 mg allopurinol tablet. The sensitization protocol was modified as a starting dose of 0.3 mg escalating to a
final dose of 300 mg/day in 2 weeks. There was no reaction during or after the desensitization. The patient’s
urate level normalized (6.3 mg/dl) and has continued on 300 mg allopurinol daily without reaction.
Conclusion: A 2 week modified allopurinol desensitization protocol is a safe alternative for elderly patients with
multiple comorbidities.
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Maculopapular exanthemaAllopurinol is a first line drug for treatment of gout and
works by inhibition of xanthine oxidase leading to de-
creased uric acid produciton [1]. Although it is a well-
tolerated drug, approximately 2% of patients treated with
allopurinol have adverse reactions such as fixed drug
eruptions (FDE), pruritic maculopapular exanthema
(MPE) and minor vasculitis whicch resolve with cessa-
tion of the drug which limits it use in these individuals
[2]. Life-threatening reactions such as DRESS; SJS or
TEN, occur very infrequently (0.2%) [3,4].
Approach to allopurinol hypersensitivity firstly in-
cludes withdrawing allopurinol, giving supportive mea-
sures such as modifying diet and alcohol intake and
corticosteroids in severe cases [3]. The other uricosuric* Correspondence: aberna.dursun@gmail.com
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article, unless otherwise stated.drugs (probenicid, benzbromarone and sulfinpyrazone)
are another option in the chronic treatment of gout [5].
When allopurinol treatment is necessary and there is no
alternative drugs in the local market, drug desensitiza-
tion should be considered except for severe hypersentiv-
ity reactions [4].
After first publication of desensitization with allopurinol
in 1976, several case reports with oral and intravenous
protocols were published [5,6]. Slow drug desensitization
protocol lasting in 28-81 days are recommended particu-
larly for elderly patients with multiple comorbidities [2].
We present a successful modified 2 weeks oral allopur-
inol desensitization in an elderly patient with multiple
comorbidities.
Case presentation
A 75 years old male was consulted due to hypersensitivty
reaction to allopurinol. He had chronic renal disease,
metastatic colorectal carcinoma status post-resection.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 2 Description of preparing allopurinol for
desensitization
Source solution 150 mg allopurinol tablet + 50 ml 5%
dextrose = 3 mg/ml
Solution A 1:10 source solution (0.3 mg/ml)
Solution B 300 mg allopurinol tablet + 50 ml 5%
dextrose = 6 mg/ml
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of drug hypersensitivity. A week after starting allopurinol
(300 mg/day), he presented to dermatology out-patient
clinic with rashes on his lower extremities. He was diag-
nosed with allopurinol-induced MPE. Allopurinol was
discontinued and he was placed on 5 days of oral cortico-
steroids. His rash resolved however, his serum urate level
rose to 19.9 mg/dl (normal range 3-7.5 mg/dl) and he ex-
perienced a gout attack. There were no alternative urate
lowering drugs in our market. Febuxostat could be ob-
tained with board report from Ministry of Health but
would take at least 3 weeks.
Due to his critic condition, a 28-days allopurinol desen-
sitization protocol was modified to 2 weeks and was per-
formed without premedication (Table 1). The protocol
was modified from a protocol developed by Gomes et al.
[5]. The soluble suspension of allopurinol was prepared by
allergy nurse practitioner as described in Table 2. Solu-
tions were well tolerated by the patient without com-
plaints. The patient was seen at the out-patient clinic on
1st, 6th, 9th, 12th and 16th days of the protocol. No reaction
occured during the desensitization or during continued
daily dosing of allopurinol 300 mg. The uric acid level
dropped to 6.3 mg/dl with therapy.
Discussion
Although allopurinol hypersensitivity is relatively un-
common, up to 2% of patients who use this drug develop
hypersensitivity reactions such as FDE, pruritic MPE
and vasculitis [2]. Despite the fact that new drugs have
been developed to treat hyperuricemia, practical therapeuticTable 1 2 weeks allopurinol desensitization protocol
DAY DRUG (Allopurinol) DOSE (ml) DOSE (mg)





6 Solution B, 6 mg/ml 3 18
7 6 36
8 10 60







16 300choices remain limited. Febuxostat is a good option for
patients with allopurinol hypersensitivity, but its acces-
sibility may be very limited in some countries [2,4]. In
this situation, desensitization procedure should be con-
sidered, except for patients with severe hypersensitivity
to allopurinol. FDE and maculopapular exanthema is
an appropriate indication for desensitization with allo-
purinol [5].
The pathophysiology underlying this hypersensitivity
reaction remains unknown, but several risk factors such
as the presence of the HLA-B58.01 allele, the dose taken
and renal failure have been proposed. Recently Yun et al.
found that allopurinol allergic patients are primarily sen-
sitized to oxypurinol. Despite the prevailing dogma that
type B adverse drug reactions are dose independent, they
concluded that allopurinol hypersensitivity is primarily
driven by oxypurinol-specific T cell response in a dose-
dependent manner, particular in the presence of HLA-
B58.01 allele [7].
Different mechanisms, including hapten inhibition,
mast cell and basophil mediator depletion, IgE con-
sumption and mast cell desensitization, have also been
proposed to explain the temporary immunological toler-
ance induced by a desensitization protocol to a drug.
The mechanism of slow desensitization is more obscure.
It has been suggested that gradually increasing antigen
doses allows metabolic adaptation resulting in increased
clearance of reactive drug metabolites [2].
There are several oral slow desensitization protocols
lasted in 28 to 81 days in the literature [5,8-10]. Time to
reach therapeutic doses is longer particularly in elderly
patients with multiple comorbidities for safety issues [2].
However if there is clinical urgency, new or modified
protocols could be tailored. The original protocol was
generated by Umperierrez et al. [9] for a patient with
FDE to allopurinol, then Gomes et al. adapted the proto-
col for also systemic reactions to allopurinol [5]. In the
Gomes study, the type of reaction was FDE in three pa-
tients, urticarial with or without angioedema in two,
anaphylaxis in one and pruritic MPE in one patient.
They reported 100% overall success rate of desensitiza-
tion with no complications in the progression of the
protocol in three patients (43%) and the remaining had
mild to moderate skin reactions [5]. Even though the
protocol was initially created for desensitization of
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firmed that it is also effective in desensitization of pa-
tients with systemic reactions [5]. Thus we also
modified the same protocol for patient with MPE to
allopurinol and the successful outcome revealed the
flexibility of slow desensitization protocols.
It is important to share new or modified drug de-
sensitization protocols, whether they have success or
not, in order to build up experiences in a field of in-
sufficient data [11]. We present a successful shortened
oral desensitization protocol for allopurinol hyper-
sensitivity. The presented case demonstrated that a
2 weeks oral allopurinol desensitization protocol can
be safely undertaken in elderly patients with multiple
comorbidities.
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